<DOC>
	<DOCNO>NCT00953758</DOCNO>
	<brief_summary>This study examine effect small molecule inhibitor Sonic Hedgehog pathway select hematologic malignancy .</brief_summary>
	<brief_title>A Study Of PF-04449913 In Select Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients select advanced hematologic malignancy refractory , resistant intolerant prior therapy . They may newly diagnose previously untreated , eligible standard treatment option , standard therapy anticipate result durable response . ECOG performance status 0 2 Adequate organ function Patients active CNS disease Patient active malignancy exception basal cell carcinoma , non melanoma skin cancer , carcinoma situ cervical skin cancer Active GVHD Grade 1 skin involvement Known malabsorption syndrome Patient active , life threaten clinically significant uncontrolled systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Chronic Myeloid Leukemia Myelofibrosis Myelodysplastic Syndrome Acute myeloid Leukemia Hedgehog inhibitor</keyword>
</DOC>